Last updated on June 2019

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC


Brief description of study

A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in advanced ALK-positive NSCLC patients who are treatment nave and to compare lorlatinib to crizotinib with respect to overall survival in the same population

Clinical Study Identifier: NCT03052608

Find a site near you

Start Over

Florida Cancer Specialists

Altamonte Springs, FL United States
  Connect »

Florida Cancer Specialists

Brandon, FL United States
  Connect »

Florida Cancer Specialists

Clearwater, FL United States
  Connect »

Florida Cancer Specialists

Gainesville, FL United States
  Connect »

Florida Cancer Specialists

Lecanto, FL United States
  Connect »

Florida Cancer Specialists

New Port Richey, FL United States
  Connect »

Florida Cancer Specialists

Orange City, FL United States
  Connect »

Florida Cancer Specialists

Orlando, FL United States
  Connect »

Florida Cancer Specialists

Saint Petersburg, FL United States
  Connect »

Florida Cancer Specialists

Spring Hill, FL United States
  Connect »

Florida Cancer Specialists

Tavares, FL United States
  Connect »

Florida Cancer Specialists

The Villages, FL United States
  Connect »

Florida Cancer Specialists

Winter Park, FL United States
  Connect »

Tennessee Oncology, PLLC

Dickson, TN United States
  Connect »

Tennessee Oncology, PLLC

Franklin, TN United States
  Connect »

Tennessee Oncology, PLLC

Gallatin, TN United States
  Connect »

Tennessee Oncology, PLLC

Hermitage, TN United States
  Connect »

Tennessee Oncology, PLLC

Lebanon, TN United States
  Connect »

Tennessee Oncology, PLLC

Murfreesboro, TN United States
  Connect »

Tennessee Oncology, PLLC

Nashville, TN United States
  Connect »

Tennessee Oncology, PLLC

Shelbyville, TN United States
  Connect »

Tennessee Oncology, PLLC

Smyrna, TN United States
  Connect »

Institut Paoli-Calmettes

Marseille cedex 09, France
  Connect »

H pital Nord

Marseille cedex 20, France
  Connect »

Service Ophtalmologie

Marseille cedex 20, France
  Connect »

Hopital Foch

Suresnes, France
  Connect »

H pital Larrey

Toulouse cedex 9, France
  Connect »

lnstitut Claudius Regaud

Toulouse cedex 9, France
  Connect »

Tuen Mun Hospital

Hong Kong, Hong Kong
  Connect »

Asan Medical Center

Seoul, Korea, Republic of
  Connect »

Ulsan University Hospital

Ulsan, Korea, Republic of
  Connect »

RBHI Kursk Regional Clinical Oncology Dispensary

Kislino, Ryshkovsky Rural Council, Russian Federation
  Connect »

Raffles Hospital

Singapore, Singapore
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.